American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary
1
Issued Date
2025-03-25
Resource Type
ISSN
24739529
eISSN
24739537
Scopus ID
2-s2.0-105000199230
Pubmed ID
39437797
Journal Title
Blood Advances
Volume
9
Issue
6
Start Page
1247
End Page
1260
Rights Holder(s)
SCOPUS
Bibliographic Citation
Blood Advances Vol.9 No.6 (2025) , 1247-1260
Suggested Citation
Siegal D.M., Tseng E.K., Schünemann H.J., Angchaisuksiri P., Cuker A., Dane K., DeSancho M.T., Diuguid D., Griffin D.O., Klok F.A., Lee A.I., Neumann I., Pai A., Righini M., Sanfilippo K.M., Terrell D.R., Akl E.A., Jabiri R.A., Jabiri Y.A., Barbara A.M., Bognanni A., Akl I.B., Boulos M., Brignardello-Petersen R., Chan M., Charide R., Colunga-Lozano L.E., Dearness K., Darzi A.J., Hussein H., Karam S.G., Kolb P., Mansour R., Morgano G.P., Morsi R.Z., Muti-Schünemann G., Nadim M.K., Noori A., Philip B.A., Piggott T., Qiu Y., Benitez Y.R., Schünemann F., Stevens A., Solo K., Wiercioch W., Mustafa R.A., Nieuwlaat R. American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary. Blood Advances Vol.9 No.6 (2025) , 1247-1260. 1260. doi:10.1182/bloodadvances.2024014219 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/108584
Title
American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary
Author(s)
Siegal D.M.
Tseng E.K.
Schünemann H.J.
Angchaisuksiri P.
Cuker A.
Dane K.
DeSancho M.T.
Diuguid D.
Griffin D.O.
Klok F.A.
Lee A.I.
Neumann I.
Pai A.
Righini M.
Sanfilippo K.M.
Terrell D.R.
Akl E.A.
Jabiri R.A.
Jabiri Y.A.
Barbara A.M.
Bognanni A.
Akl I.B.
Boulos M.
Brignardello-Petersen R.
Chan M.
Charide R.
Colunga-Lozano L.E.
Dearness K.
Darzi A.J.
Hussein H.
Karam S.G.
Kolb P.
Mansour R.
Morgano G.P.
Morsi R.Z.
Muti-Schünemann G.
Nadim M.K.
Noori A.
Philip B.A.
Piggott T.
Qiu Y.
Benitez Y.R.
Schünemann F.
Stevens A.
Solo K.
Wiercioch W.
Mustafa R.A.
Nieuwlaat R.
Tseng E.K.
Schünemann H.J.
Angchaisuksiri P.
Cuker A.
Dane K.
DeSancho M.T.
Diuguid D.
Griffin D.O.
Klok F.A.
Lee A.I.
Neumann I.
Pai A.
Righini M.
Sanfilippo K.M.
Terrell D.R.
Akl E.A.
Jabiri R.A.
Jabiri Y.A.
Barbara A.M.
Bognanni A.
Akl I.B.
Boulos M.
Brignardello-Petersen R.
Chan M.
Charide R.
Colunga-Lozano L.E.
Dearness K.
Darzi A.J.
Hussein H.
Karam S.G.
Kolb P.
Mansour R.
Morgano G.P.
Morsi R.Z.
Muti-Schünemann G.
Nadim M.K.
Noori A.
Philip B.A.
Piggott T.
Qiu Y.
Benitez Y.R.
Schünemann F.
Stevens A.
Solo K.
Wiercioch W.
Mustafa R.A.
Nieuwlaat R.
Author's Affiliation
Faculty of Dentistry
School of Medicine
Ramathibodi Hospital
L’École de médecine
Canadian Agency for Drugs and Technologies in Health
Asklepios Klinik Wandsbek
McMaster University Medical Centre
American University of Beirut
McMaster University
Università degli Studi di Milano
University of Oklahoma Health Sciences Center
The University of Chicago
University of Kansas School of Medicine
McMaster University, Faculty of Health Sciences
Universitätsklinikum Freiburg
Penn Medicine
Washington University School of Medicine in St. Louis
New York Presbyterian Hospital
Yale School of Medicine
Kaiser Permanente
St. Michael's Hospital, Toronto
University of Toronto
Queen’s University
Leids Universitair Medisch Centrum
Faculty of Medicine - Ain Shams University
Institut de Cardiologie de l'Université d'Ottawa
Vagelos College of Physicians and Surgeons
St. Joseph's Healthcare Hamilton
Washington University in St. Louis
Hôpitaux Universitaires de Genève
Universidad de Guadalajara
University of Kansas Medical Center
Toronto Western Hospital
The Johns Hopkins Hospital
Universidad San Sebastián
Optum Tristate
Division of Hematology
School of Medicine
Ramathibodi Hospital
L’École de médecine
Canadian Agency for Drugs and Technologies in Health
Asklepios Klinik Wandsbek
McMaster University Medical Centre
American University of Beirut
McMaster University
Università degli Studi di Milano
University of Oklahoma Health Sciences Center
The University of Chicago
University of Kansas School of Medicine
McMaster University, Faculty of Health Sciences
Universitätsklinikum Freiburg
Penn Medicine
Washington University School of Medicine in St. Louis
New York Presbyterian Hospital
Yale School of Medicine
Kaiser Permanente
St. Michael's Hospital, Toronto
University of Toronto
Queen’s University
Leids Universitair Medisch Centrum
Faculty of Medicine - Ain Shams University
Institut de Cardiologie de l'Université d'Ottawa
Vagelos College of Physicians and Surgeons
St. Joseph's Healthcare Hamilton
Washington University in St. Louis
Hôpitaux Universitaires de Genève
Universidad de Guadalajara
University of Kansas Medical Center
Toronto Western Hospital
The Johns Hopkins Hospital
Universidad San Sebastián
Optum Tristate
Division of Hematology
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: COVID-19–related critical and acute illness is associated with an increased risk of venous thromboembolism (VTE). These evidence-based recommendations of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about using anticoagulation for thromboprophylaxis for patients with COVID-19–related critical illness; patients with COVID-19–related acute illness; and those being discharged from the hospital, who do not have suspected or confirmed VTE. Methods: ASH formed a multidisciplinary panel, including patient representatives. The Michael G. DeGroote Cochrane Canada and MacGRADE Centres at McMaster University supported guideline development, including performing systematic reviews (up to June 2023). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess certainty in the evidence and make recommendations. Results: This is an executive summary of 3 updated recommendations that have been published, which concludes the living phase of the guidelines. For patients with COVID-19–related critical illness, the panel issued conditional recommendations suggesting (a) prophylactic-intensity over therapeutic-intensity anticoagulation and (b) prophylactic-intensity over intermediate-intensity anticoagulation. For patients with COVID-19–related acute illness, conditional recommendations were suggested (a) prophylactic-intensity over intermediate-intensity anticoagulation, and (b) therapeutic-intensity over prophylactic-intensity anticoagulation. The panel issued a conditional recommendation suggesting against the use of postdischarge anticoagulant thromboprophylaxis. Conclusions: These conditional recommendations were made based on low or very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials for patients with COVID-19.